更昔洛韦在D+/R+肾移植术后预防CMV 感染的疗效观察

目的:观察D+/R+肾移植术后人群应用更昔洛韦预防巨细胞病毒感染的疗效与安全性。方法:我院2003年5月至2011年11月期间D+/R+同种异体肾移植患者93例,肾移植术后预防性应用更昔洛韦,对移植后1年内巨细胞病毒的感染率、感染发生的时间及有症状的CMV发病率进行以及用药后不良事件进行分析。结果:在D+/R+肾移植人群中预防性使用更昔洛韦后的感染率为28%,有症状的CMV发病率4.3%,病毒血症的平均感染时间为231.3 d,严重不良事件发生率为45.1%。结论:在D+/R+肾移植术后患者中预防性更昔洛韦能够预防CMV感染并且延长CMV初次感染时间,使D+/R+肾移植患者获益。     

表达Rta的杆状病毒载体和更昔洛韦联用治疗鼻咽癌的实验研究

目的 联合使用一种新的表达Epstein Barr病毒（EBV）裂解性复制极早期基因Rta的杆状病毒载体及抗病毒药物更昔洛韦,试验其对激活鼻咽癌细胞中潜伏性EBV的复制和杀伤肿瘤细胞的作用。方法 用携带EBV的复制起点OriP和CMV启动子表达Rta基因的重组杆状病毒处理EBV潜伏感染的鼻咽癌细胞Hone1-EBV,和由该细胞系建立的裸鼠肿瘤模型,同时联合使用更昔洛韦,研究细胞和肿瘤生长的情况。结果 重组杆状病毒和更昔洛韦联合处理肿瘤细胞后,细胞生长活性仅为对照的51%,裸鼠活体实验中肿瘤生长也受到明显的抑制,10 d后瘤体积仅为对照的20%,瘤重仅为对照的30%。组织化学分析证实大量肿瘤细胞坏死。结论 杆状病毒载体与更昔洛韦联合可以用于EBV相关的鼻咽癌的治疗。     

利用孕早期人胚绒毛组织进行先天性巨细胞病毒感染诊断的研究

新生儿出生缺陷已成为影响人口素质的重要因素。在引起出生缺陷的诸因素中,宫内病毒感染是一个重要原因。风疹病毒等对胎儿的影响早巳为人们所熟悉,而巨细胞病毒(cytomegalovirus,CMV)对胎儿的危害,近年来已受到人们的重视。据国内外调查,在新生儿中先天性CMV感染的发生率在0.5—2.0％之间。目前对先天性CMV感染的研究主要用新生儿尿样和脐带血作为研究材料。从产前诊断的角度考虑,     

更昔洛韦联合大剂量丙种球蛋白治疗婴儿巨细胞病毒性肝炎的疗效观察

目的:研究更昔洛韦联合大剂量丙种球蛋白治疗婴儿巨细胞病毒性(CMV)肝炎的临床疗效,为婴儿CMV肝炎的抗菌治疗提供理论依据。方法:选取我院自2009年7月至2016年1月收治的103例CMV肝炎婴儿,根据随机数字表法分为治疗组58例,对照组45例。两组患儿均常规给予退黄、保肝药物治疗,对照组在此基础上给予更昔洛韦治疗,治疗组给予大剂量丙种球蛋白联合更昔洛韦治疗。对比观察两组患儿治疗后黄疸消退情况、肝功能变化、血CMV-IgM和尿CMV-DNA转阴情况、肝和脾B超变化、治疗效果及不良反应情况。结果:治疗组患儿黄疸消退时间、血CMV-IgM和尿CMV-DNA转阴时间均短于对照组(P0.05);治疗组肝功能指标包括总胆红素(TBIL)、直接胆红素(DBIL)、丙氨酸氨基转移酶(ALT)、γ-谷氨酰转肽酶(GGT)水平均较对照组和治疗前降低(P0.05);治疗后两组肝、脾明显减小,且治疗组减小更显著,差异有统计学意义(P0.05);治疗组中血CMV-IgM转阴率、尿CMV-DNA转阴率、治疗总有效率均高于对照组(P0.05);治疗组不良反应发生率低于对照组(P0.05)。结论:更昔洛韦联合大剂量丙种球蛋白治疗婴儿CMV肝炎临床效果良好,可以有效缓解黄疸症状,恢复肝脏功能,肝、脾回缩明显,不良反应少,值得推广。     

风疹病毒包膜糖蛋白分子生物学研究进展

风疹病毒（rubella virus,RV）是披膜病毒科风疹病毒属的唯一成员,是最常见、最重要的TORCH综合征病原体之一。其感染的危害主要在于先天性感染,孕妇在妊娠期、特别是妊娠前3个月感染RV,可引起胎儿宫内感染,产生先天性风疹综合征（congenital rubella syndrome,CRS）,造成婴儿全身多种器官发育畸形或功能异常,如白内障、耳聋、先天性心脏病等,严重时可出现死胎或流产。因此,许多国家把风疹疫苗纳入计划免疫。但目前临床应用的风疹疫苗均为减毒活疫苗,其中的RV能通过胎盘感染胎儿,仍有致畸的危险性,故妊娠早期的妇女无法使用该疫苗预防风疹感染。     

先天性CMV感染致中枢神经系统畸形发育机制

胎儿中枢神经系统(central nervous system,CNS)是人类巨细胞病毒(human cytomegalovirus,HCMV)先天性感染的主要靶器官。胚胎期CMV感染常常导致严重CNS畸形的发生,其前提条件是CNS中的神经前体(干)细胞、神经元及神经胶质细胞对CMV普遍易感。发育期CNS感染CMV具有以下特点:⑴神经系统细胞对CMV的容纳性在CNS的不同发育阶段有所不同;⑵受累的细胞数随着发育的进展而增多;⑶CNS不同部位的细胞对CMV的敏感性存在明显的差异;⑷感染发生时细胞所处细胞周期的时相也与感染严重程度密切相关。CMV感染能诱导宿主细胞特异性的染色体折断,影响Homeobox基因(胚胎发育的主控基因)的表达,进而阻断细胞周期(G1期滞留)、诱导细胞凋亡,导致CNS细胞数量减少与迁徙异常,最终导致C N S发育畸形。     

多发性骨髓瘤患者硼替佐米治疗相关带状疱疹发病机理及预防策略研究进展

含硼替佐米的化疗方案目前是多发性骨髓瘤的一线治疗方案,研究表明,该方案同时会使患者带状疱疹的发生率增加。硼替佐米治疗致带状疱疹激活的机理以及如何进行合理的预防是临床医师需要解决的问题。阿昔洛韦是第一代无环鸟苷类药物,伐昔洛韦是阿昔洛韦的前体药物,目前阿昔洛韦和伐昔洛韦可用于接受含硼替佐米化疗方案的MM患者带状疱疹的预防。本文对近年来多发性骨髓瘤患者应用硼替佐米后带状疱疹发生的相关机理及预防策略作一综述。     

痰热清与更昔洛韦佐治小儿支气管肺炎疗效观察

目的观察比较痰热清与更昔洛韦佐治小儿支气管肺炎的疗效。方法将246例支气管肺炎患儿随机分为3组,痰热清组82例,更昔洛韦组70例,对照组94例(采用常规抗生素治疗),2个实验组在常规抗生素药物治疗的基础上分别加用痰热清和更昔洛韦静滴,比较3组患儿的发热、咳嗽、肺部体征消失时间。结果痰热清组疗效较好,更昔洛韦组次之,对照组较差;2个实验组患儿的发热、咳嗽、肺部啰音消失时间均短于对照组,且痰热清组咳嗽、肺部啰音消失时间比更昔洛韦组更短。结论在常规抗生素药物治疗的基础上应用痰热清、更昔洛韦治疗小儿支气管肺炎,能迅速缓解症状、缩短疗程;且痰热清的治疗效果最佳。     

更昔洛韦治疗小儿EB病毒感染的临床分析

目的:探讨更昔洛韦治疗小儿EB病毒感染的临床效果。方法:本次研究的70例EB病毒感染患儿均为我院在2012年12月到2014年12月期间收治,将其按照治疗方式的不同分为观察组35例和对照组35例,对照组采取常规对症治疗,观察组患者在对照组治疗基础上增加更昔洛韦治疗,对比两组患者的治疗效果。结果:观察组治疗总有效率为98.18%,其不良反应发生率为8.57%;对照组治疗总有效率为72.73%,其不良反应发生率为22.86%。两组比较差异有统计学意义(P0.05)。结论:更昔洛韦治疗小儿EB病毒感染的临床效果显著,安全性较高,可在临床上使用。     

病毒的母子感染

<正> 本文主要叙述在妊娠中和分娩前后,母体的病毒感染对胎儿或新生儿的影响。 1.母体的感染时期:母体在妊娠早期初次感染风疹,将引起胎儿先天性风疹综合征。在分娩时感染单纯性疱疹病毒(HSV),能引起新生儿全身性疱疹。母体在妊娠中感染风疹、巨细胞病毒(CMV)、人乳头状瘤病毒(HPV);在分娩时感染HSV、乙     

Seroprevalence of Cytomegalovirus,Epstein Barr Virus and Varicella Zoster Virus among Pregnant Women in Bradford: A Cohort Study

Objective

To estimate the seroprevalence of cytomegalovirus (CMV), Epstein Barr virus (EBV) and varicella zoster virus (VZV) among pregnant women in Bradford by ethnic group and country of birth.

Methods

A stratified random sample of 949 pregnant women enrolled in the Born in Bradford birth cohort was selected to ensure sufficient numbers of White UK born women, Asian UK born women and Asian women born in Asia. Serum samples taken at 24-28 weeks’ gestation were tested for CMV IgG, EBV IgG and VZV IgG. Each woman completed a questionnaire which included socio-demographic information.

Results

CMV seroprevalence was 49% among the White British women, 89% among South Asian UK born women and 98% among South Asian women born in South Asia. These differences remained after adjusting for socio-demographic factors. In contrast, VZV seroprevalence was 95% among women born in the UK but significantly lower at 90% among South Asian women born in Asia. EBV seroprevalence was 94% overall and did not vary by ethnic group/country of birth.

Conclusions

Although about half of White British women are at risk of primary CMV infection in pregnancy and the associated increased risk of congenital infection, most congenital CMV infections are likely to be in children born to South Asian women with non-primary infection during pregnancy. South Asian women born in South Asia are at risk of VZV infection during pregnancy which could produce congenital varicella syndrome or perinatal chickenpox. Differences in CMV and VZV seroprevalence by ethnic group and country of birth must be taken into account when universal immunisation against these viruses is contemplated.     

Malformations of cortical development in children with congenital cytomegalovirus infection - A study of nine children with proven congenital cytomegalovirus infection

Congenital cytomegalovirus (CMV) infection is the most common vertically transmitted disease with the rate of the infection ranging from 0.2 to 2.4% in newborn infants. Congenital CMV infection causes multiorgan affection, but the most severe and permanent sequelae are those affecting central nervous system such as mental retardation, cerebral palsy, sensorineural hearing loss, chorioretinitis and seizures as a result of direct interference of the virus with neurogenesis. The time of acquiring infection is strongly connected to the level of child's disability. Infection in early pregnancy results in severe neurological sequelae, while later infection has less prominent signs. Radiological findings show connection between onset of infection and brain imaging, from lissencephaly, pachygyria, polymicrogyria, schizencephaly, calcification, cerebellar hypoplasia and/or hypoplasia/agenesis of corpus callosum as a result of an early infection, to white matter abnormalities including disturbed myelination as a result of a late infection. We present nine patients with proven congenital CMV infection and malformations of cortical development and their computed tomography/magnetic resonance (CT/MRI) findings along with clinical assessments. According to CT/MRI results we assume that two of our children with lissencephaly had an early onset of infection. The other seven with less severe cortical dysplasia in form of pachy/polymicrogyria were probably infected later Cerebellar hypoplasia and/or calcifications in our patients also confirm an early onset of infection. Developmental outcome in all of our children was poor: moderate to severe psychomotor retardation has been diagnosed in all children; five of them have developed cerebral palsy (four have bilateral spastic and one dyskinetic) and one is estimated to have minor motor dysfunction. Seven out of nine developed epilepsy, chorioretinitis was found in three of them and sensorineural deafness in two of them. All of our children, except one, were presented by symptomatic infection, yet only four of them were recognized at birth. Therefore, congenital CMV infection should be considered as one of the reasons for childhood disability more often.     

Prevalence of maternal cytomegalovirus (CMV) antibody and detection of CMV DNA in amniotic fluid.

The prevalence of cytomegalovirus (CMV) IgG antibody was determined in 573 pregnant women in the first trimester. The overall prevalence of CMV IgG antibody was 77.5%. The rate of seropositivity was 67.7% in women < 25 yr, and increased with age to 85.7% in women 40 yr. These results imply that young women in Japan are at increased risk for primary CMV infection during pregnancy and that congenital CMV infection rates might increase in the future. We conducted a prospective study of 75 pregnant women who underwent amniocentesis for various indications to determine if CMV DNA could be detected in the amniotic fluid. None had symptoms associated with CMV infection, CMV IgM antibody, or seroconversion to CMV IgG antibody during pregnancy. CMV DNA was not detected in the amniotic fluid using a polymerase chain reaction assay. The 65 fetuses, including 3 sets of twins, were followed through birth. CMV DNA was not detected in urine samples obtained within the first 2 weeks of life. In conclusion, CMV DNA was not detected in the amniotic fluid of women who did not have CMV infection. These results, however, suggest that the negative predictive value of prenatal amniotic fluid analysis is high and that the presence of CMV DNA in the amniotic fluid has clinical significance for the diagnosis of congenital CMV infection if detected in pregnant women.     

Evaluation of the indirect and IgM‐capture anti‐human cytomegalovirus IgM ELISA methods as confirmed by cytomegalovirus IgG avidity

Primary cytomegalovirus (CMV) infection during pregnancy often results in congenital CMV infection with severe clinical complications. IgM antibodies are one of the indices of primary infection. The IgG avidity index (AI) is also known to remain low for 3 months after primary infection. Here, we evaluated and compared the performance of CMV IgM and IgG avidity assays. Because sensitivity and specificity reportedly differ between CMV IgM kits, CMV IgM detection was compared between the two commercially available ELISA kits that are most commonly used in Japan. Sera for CMV IgM were first screened using a traditional indirect ELISA kit. Selected samples were then tested for CMV IgM and CMV AI using a CMV IgM‐capture ELISA kit and a CMV IgG avidity assay, respectively. The rate of concordance between the IgM kits was 89% (42/47), indicating the absence of any significant difference. Most of the CMV IgM‐positive plasma samples showed high CMV IgG AI; however, 18 commercially available plasma samples with low CMV IgG AI were all CMV IgM‐positive. One plausible explanation for this discrepancy is that the duration of low IgG AI is shorter than that of IgM positivity. Alternatively, CMV IgM tests may generate pseudo‐positive readouts in cases of congenital infection. Nevertheless, our study confirms that CMV IgG AI can be a reliable indicator of CMV primary infection.     

Congenital toxoplasmosis: epidemiologic features and control.

Toxoplasmosis is caused by the parasite Toxoplasma gondii. It is acquired from undercooked meat or from food or fomites contaminated by cat feces. The disease can be transmitted to the fetus only during maternal parasitemia, which is associated with primary infection. Extrapolation from current data suggests that there are 140 to 1400 cases of congenital toxoplasmosis per year in Canada and that 70 to 280 of the infants are severely affected at birth; many of the others suffer sequelae later in life. Serologic diagnosis of primary infection in the mother is quite sensitive and specific. Diagnosis in the infant is more difficult and may take several months. Prenatal treatment of the woman and postnatal treatment of the infant are hampered by the lack of proven efficacy as well as ethical and compliance problems. Preventive serologic screening and prophylaxis have the same drawbacks. Educating young women to avoid infection is an inexpensive, low-risk intervention that would be the preferred preventive strategy if it could be shown to be effective. Immunization may prove to be the most cost-effective method of preventing congenital toxoplasmosis if a safe and effective vaccine is developed.     

Nonhuman primate models of intrauterine cytomegalovirus infection

Congenital human cytomegalovirus (HCMV) infection has long been recognized as a threat to the developing fetus, even though studies have shown that only a subset of congenital infections results in clinical signs of disease. Among the estimated 8000 children who develop sequelae from congenital CMV infection each year in the United States alone, most suffer permanent developmental defects within the central nervous system. Because there is currently no approved vaccine for HCMV, and anti-HCMV drugs are not administered to gravid women with congenital infection because of potential toxicity to the fetus, there is a clear clinical need for effective strategies that minimize infection in the mother, transplacental transmission of the virus, and/or fetal disease. Animal models provide a method to understand the mechanisms of HCMV persistence and pathogenesis, and allow for testing of novel strategies that limit prenatal infection and disease. The rhesus macaque model is especially well suited for these tasks because monkeys and humans share strong developmental, immunological, anatomical, and biochemical similarities due to their close phylogenetic relationship. This nonhuman primate model provides an invaluable system to accelerate the clinical development of promising new therapies for the treatment of human disease. This review addresses salient findings with the macaque model as they relate to HCMV infection and potential avenues of discovery, including studies of intrauterine CMV infection. The complexity of the natural history of HCMV is discussed, along with the ethical and logistical issues associated with studies during pregnancy, the recent contributions of animal research in this field of study, and future prospects for increasing our understanding of immunity against HCMV disease.     

Human cytomegalovirus inhibits neuronal differentiation and induces apoptosis in human neural precursor cells

Human cytomegalovirus (HCMV) is the most common cause of congenital infections in developed countries, with an incidence varying between 0.5 and 2.2% and consequences varying from asymptomatic infection to lethal conditions for the fetus. Infants that are asymptomatic at birth may still develop neurological sequelae, such as hearing loss and mental retardation, at a later age. Infection of neural stem and precursor cells by HCMV and consequent disruption of the proliferation, differentiation, and/or migration of these cells may be the primary mechanism underlying the development of brain abnormalities. In the present investigation, we demonstrate that human neural precursor cells (NPCs) are permissive for HCMV infection, by both the laboratory strain Towne and the clinical isolate TB40, resulting in 55% and 72% inhibition of induced differentiation of human NPCs into neurons, respectively, when infection occurred at the onset of differentiation. This repression of neuronal differentiation required active viral replication and involved the expression of late HCMV gene products. This capacity of HCMV to prevent neuronal differentiation declined within 24 h after initiation of differentiation. Furthermore, the rate of cell proliferation in infected cultures was attenuated. Surprisingly, HCMV-infected cells exhibited an elevated frequency of apoptosis at 7 days following the onset of differentiation, at which time approximately 50% of the cells were apoptotic at a multiplicity of infection of 10. These findings indicate that HCMV has the capacity to reduce the ability of human NPCs to differentiate into neurons, which may offer one explanation for the abnormalities in brain development associated with congenital HCMV infection.     

The role of IgG avidity in diagnosis of cytomegalovirus infection in newborns and infants

To evaluate the value of IgG avidity in diagnosis of congenital cytomegalovirus (CMV) infection in newborns and infants we collected serum samples from 40 infants under 12 months of age with suspected congenital CMV infection. Sera were tested for IgM, IgG and IgG avidity. For 25 of them, virus isolation and/or polymerase chain reaction (PCR) on urine specimens were performed. Thirteen (32.5%) patients showed the presence of CMV IgM antibodies, 3 (7.5%) had equivocal IgM result, and 24 (60.0%) patients had IgG antibodies only. Using IgG avidity, CMV infection (low avidity index-AI) was documented in 61.5% IgM positive and 54.2% IgM negative patients. Eight of nine (88.8%) IgM positive patients were positive either on virus isolation or PCR. In IgM negative patients, 46.6% urine cultures were positive for CMV and 66.6% were PCR positive. According to age, IgG avidity demonstrated acute/recent primary CMV infection in 58.8% patients younger than three months compared with 91.7% and 81.8% in 3-6 and 6-12 months old babies, respectively. In conclusion, IgG avidity is useful in diagnosis of CMV infection either in IgM positive or IgM negative children older than 3 months of age. In infants less than 3 months, transplacentally derived maternal IgG antibodies of high avidity influence on the IgG avidity result. In these children, CMV infection should be confirmed by direct virologic methods such as virus isolation or PCR.     

Mother-to-fetus transmission of cytomegalovirus. A review

Congenital human cytomegalovirus (CMV) infection is the leading infectious cause of mental retardation, sensorineural deafness and visual impairment. It is mainly related to a primary maternal infection. The placenta should be considered the most important site of both the protection of the fetus from CMV infection and the transmission of CMV from mother to fetus. The control of the passage of CMV across the placenta probably involves a cascade of regulatory events. Roles are played by factors relating to the host immune-selective pressures, such as local cytokines and maternal CMV-specific neutralizing antibodies. The presence of other pathogens at the maternal-fetal interface also influences the outcome of CMV infection. Further investigations are needed in which clinical CMV strains are applied in in vitro studies to unravel the molecular mechanism of the intrauterine transmission of CMV and to elucidate the complex regulation that leads to prevention of the in utero transmission of CMV in vivo.     

Genotype Distribution,Viral Load and Clinical Characteristics of Infants with Postnatal or Congenital Cytomegalovirus Infection

Background

Congenital cytomegalovirus infection is a leading cause of long-term sequelae. Cytomegalovirus is also frequently transmitted to preterm infants postnatally, but these infections are mostly asymptomatic. A correlation between cytomegalovirus genotypes and clinical manifestations has been reported previously in infants with congenital infection, but not in preterm infants with postnatal infection.

Objectives

The main objective of this study was to investigate cytomegalovirus genotype distribution in postnatal and congenital cytomegalovirus infection and its association with disease severity.

Methods

Infants admitted to the neonatal intensive care unit of the University Medical Center Utrecht, The Netherlands between 2003–2010 and diagnosed with postnatal or congenital cytomegalovirus infection were included. Classification of cytomegalovirus isolates in genotypes was performed upon amplification and sequencing of the cytomegalovirus UL55 (gB) and UL144 genes. Clinical data, cerebral abnormalities, neurodevelopmental outcome and viral load were studied in relation to genotype distribution.

Results

Genotyping results were obtained from 58 preterm infants with postnatal cytomegalovirus infection and 13 infants with congenital cytomegalovirus infection. Postnatal disease was mild in all preterm infants and all had favourable outcome. Infants with congenital infection were significantly more severely affected than infants with postnatal infection. Seventy-seven percent of these infants were symptomatic at birth, 2/13 died and 3/13 developed long-term sequelae (median follow-up 6 (range 2–8) years). The distribution of cytomegalovirus genotypes was comparable for postnatal and congenital infection. UL55 genotype 1 and UL144 genotype 3 were predominant genotypes in both groups.

Conclusions

Distribution of UL55 and UL144 genotypes was similar in asymptomatic postnatal and severe congenital CMV infection suggesting that other factors rather than cytomegalovirus UL55 and UL144 genotype are responsible for the development of severe disease.